Rucaparib
Brand: Rubraca (global) / Rucaparib (IN/BD)
Anticancer
PARP inhibitor
Pharmacokinetics
| Half-life | 17 hours |
| Tmax | 1.9 h |
| Protein Binding | 70 % |
| Volume of Distribution | 2.3 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Dose reduction in hepatic impairment required. Monitor LFTs and renal function. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Nausea, vomiting, anemia, increased ALT/AST
Contraindications:
Severe hepatic impairment
Precautions:
Monitor liver enzymes regularly
half-life ~17 hours
max dose = 600 mg/day (300 mg twice daily)